New nasal spray COVID booster enters human testing
NCT ID NCT07536308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new COVID-19 booster vaccine called OCU500, which is given as a nasal spray or inhaled mist instead of a shot. The study involves 80 healthy adults aged 18-64 who have already been vaccinated against COVID-19. Researchers are checking if the vaccine is safe and whether it triggers a strong immune response in the nose and blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OCU500 (a COVID-19 booster vaccine given as a nasal spray or inhaled mist)
What this could lead to
If it works, this could provide a more convenient and potentially more protective booster against COVID-19, especially against newer variants.
What could go wrong
This is a very early Phase 1 trial with only 80 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115-6110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saint Louis University Center for Vaccine Development
RECRUITINGSt Louis, Missouri, 63104-1015, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Hope Clinic of Emory University
RECRUITINGDecatur, Georgia, 30030-1705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
RECRUITINGBaltimore, Maryland, 21201-1509, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Medical Branch
RECRUITINGGalveston, Texas, 77555-0435, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit
WITHDRAWNSt Louis, Missouri, 63110, United States